This report on global multiple drug resistance bacteria infection treatment market studies various vectors and drug class. Rising prevalence of antimicrobial drug resistance and increasing demand for rapid diagnostic testing kits will propel the multiple drug resistance bacterial infection treatment market growth. The limiting factors related to this market are the complex regulatory approvals for the antibiotics which varies according to countries. Promising pipeline of novel antibiotics with more effective mechanism of action to counteract drug resistance by microbes will result into deep market penetration of the multiple drug resistance bacterial infection treatment market.
For the purpose of this study, the vectors studied include critical, high and medium ; drug class studied for the purpose of this research are segmented as cephalosporins, beta lactams, beta lactamase inhibitors, oxazolidinone, cyclic lipopeptide, glycolipopeptides and others.
This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global multiple drug resistance bacterial infection treatment market. Competition assessment tools such as market attractiveness assessment and competitive landscape analysis by key players are also demonstrated in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the global multiple drug resistance bacterial infection treatment market. The key players profiled in this report are Abbott Laboratories, Inc., Actelion Pharmaceuticals Ltd., Albany Molecular Research, Inc., Allergan plc, AstraZeneca, Bayer AG, Biocon, Daiichi Sankyo Company, GlaxoSmithKline plc, Macrolide Pharmaceuticals, Inc., Merck & Co, Inc., Pfizer, Inc., Sanofi, Teva Pharmaceuticals Industries Ltd., Wockhardt, Zavante Therapeutics, Inc., and other notable players.
Antibiotic resistance is accelerated by the misuse and overuse of antibiotics, as well as poor infection prevention and control. World Health Organization (WHO) 2015 awareness guidelines suggest that in order to prevent and control antibiotic resistance use only the prescribed antibiotics, never share or use leftover antibiotics and prevent infection by maintaining personal hygiene, consumption of hygienic food and water, practice safe sex and keep vaccination up to date. The factors responsible for the growth of the multiple drug resistance bacterial infection treatment market are, rising prevalence of antibiotic resistance and promising pipeline to counteract existing drug resistance. In 2016 the beta Lactam drugs held the largest market due to factors such as rising prevalence of Enterobacteriaceae and Pseudomonas aeruginosa carbapenem resistance, and broad spectrum activity delivered by beta lactam drugs such as Ceftazidime-avibactam and Doripenem. Oxazolidinone and Glycolipopeptides will be the fastest growing segments throughout the forecast period 2017-2025, majorly due to factors such as increasing patient pool suffering with Enterococcus faecium and Staphylococcus aureus methicillin and vancomycin resistance, improved pharmacodynamic activity shown by drugs such as Linezolid and Dalbavancin. Overall, the global multiple drug resistance bacterial infection treatment market is highly competitive with presence of multiple players like Abbott Laboratories, Inc., Actelion Pharmaceuticals Ltd., Albany Molecular Research, Inc., Allergan plc, AstraZeneca, Bayer AG, Biocon, Daiichi Sankyo Company, GlaxoSmithKline plc, Macrolide Pharmaceuticals, Inc., Merck & Co, Inc., Pfizer, Inc., Sanofi, Teva Pharmaceuticals Industries Ltd., Wockhardt, Zavante Therapeutics, Inc., and other notable players etc. specializing in respective fields. Consolidation activities are being increasingly witnessed on the competitive front with a view to increase the novel antibiotics to counteract drug resistance and better pharmacokinetic activities for better patient compliance and available at low cost.
As per the Assistant Secretary for Preparedness and Response (ASPR) 2015 report of Department of Health and Human Services over the past 15 years there has been 15 entries and 36 corporate exits involved in the antimicrobial treatment. In 2016, the critical vector segment held the largest market in the multiple drug resistance bacterial infection treatment market chiefly due to factors such as rising prevalence of Enterobacteriaceae and Pseudomonas aeruginosa Carbapenem resistance cases and lack of novel drug launch in the Beta lactam antibiotics will serve great opportunity for budding industries to reclaim new grounds to fortify their product portfolio. High segment will be the fastest growing market throughout the forecast period 2017-2025, due to the extensive growth in the Helicobacter pylori (clarithromycin-resistant), and Staphylococcus aureus, (methicillin-resistant, vancomycin-intermediate and resistant) infections and recent launch of novel drug formulation Pylera used to overcome clarithromycin resistance in peptic ulcer treatment; drugs such as linezolid, Daptomycin and Dalvabancin has effective mechanism of action in comparison to vancomycin in the antibiotic resistance treatment.
North America was observed as the largest market for multiple drug resistance bacterial infection treatment market in the base year 2021. According to Department of Health and Human Services of CDC report 2015 approximately 23,000 Americans die each year due to antimicrobial drug resistance; the growth is attributed mainly due to rising prevalence of multiple drug resistance cases, evolved health infrastructure and affordable reimbursement scenario. According to the European Centre for Disease Prevention and Control approximately 25,000 deaths were associated with multidrug resistant bacterial infection; the growth is chiefly attributed due to high public awareness regarding multiple drug resistance leading to early diagnosis and treatment, and supportive regulatory approval for launch of new antibiotics for the treatment of multiple drug resistance. Asia Pacific will be the fastest growing regional segment throughout the forecast period 2022-2030, the growth is attributed by factors like rising prevalence of geriatric population suffering with multiple drug resistance bacterial infection and increasing disposable income in these regions. Factors such as developing health infrastructure, increasing awareness regarding the judicious use of prescribed antibiotics especially in the remote areas are going to fuel the rapid growth of multiple drug resistance bacterial infection treatment market in Latin America and Middle East and Africa region in the near future.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
This product will be delivered within 2 business days.
For the purpose of this study, the vectors studied include critical, high and medium ; drug class studied for the purpose of this research are segmented as cephalosporins, beta lactams, beta lactamase inhibitors, oxazolidinone, cyclic lipopeptide, glycolipopeptides and others.
This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global multiple drug resistance bacterial infection treatment market. Competition assessment tools such as market attractiveness assessment and competitive landscape analysis by key players are also demonstrated in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the global multiple drug resistance bacterial infection treatment market. The key players profiled in this report are Abbott Laboratories, Inc., Actelion Pharmaceuticals Ltd., Albany Molecular Research, Inc., Allergan plc, AstraZeneca, Bayer AG, Biocon, Daiichi Sankyo Company, GlaxoSmithKline plc, Macrolide Pharmaceuticals, Inc., Merck & Co, Inc., Pfizer, Inc., Sanofi, Teva Pharmaceuticals Industries Ltd., Wockhardt, Zavante Therapeutics, Inc., and other notable players.
Antibiotic resistance is accelerated by the misuse and overuse of antibiotics, as well as poor infection prevention and control. World Health Organization (WHO) 2015 awareness guidelines suggest that in order to prevent and control antibiotic resistance use only the prescribed antibiotics, never share or use leftover antibiotics and prevent infection by maintaining personal hygiene, consumption of hygienic food and water, practice safe sex and keep vaccination up to date. The factors responsible for the growth of the multiple drug resistance bacterial infection treatment market are, rising prevalence of antibiotic resistance and promising pipeline to counteract existing drug resistance. In 2016 the beta Lactam drugs held the largest market due to factors such as rising prevalence of Enterobacteriaceae and Pseudomonas aeruginosa carbapenem resistance, and broad spectrum activity delivered by beta lactam drugs such as Ceftazidime-avibactam and Doripenem. Oxazolidinone and Glycolipopeptides will be the fastest growing segments throughout the forecast period 2017-2025, majorly due to factors such as increasing patient pool suffering with Enterococcus faecium and Staphylococcus aureus methicillin and vancomycin resistance, improved pharmacodynamic activity shown by drugs such as Linezolid and Dalbavancin. Overall, the global multiple drug resistance bacterial infection treatment market is highly competitive with presence of multiple players like Abbott Laboratories, Inc., Actelion Pharmaceuticals Ltd., Albany Molecular Research, Inc., Allergan plc, AstraZeneca, Bayer AG, Biocon, Daiichi Sankyo Company, GlaxoSmithKline plc, Macrolide Pharmaceuticals, Inc., Merck & Co, Inc., Pfizer, Inc., Sanofi, Teva Pharmaceuticals Industries Ltd., Wockhardt, Zavante Therapeutics, Inc., and other notable players etc. specializing in respective fields. Consolidation activities are being increasingly witnessed on the competitive front with a view to increase the novel antibiotics to counteract drug resistance and better pharmacokinetic activities for better patient compliance and available at low cost.
As per the Assistant Secretary for Preparedness and Response (ASPR) 2015 report of Department of Health and Human Services over the past 15 years there has been 15 entries and 36 corporate exits involved in the antimicrobial treatment. In 2016, the critical vector segment held the largest market in the multiple drug resistance bacterial infection treatment market chiefly due to factors such as rising prevalence of Enterobacteriaceae and Pseudomonas aeruginosa Carbapenem resistance cases and lack of novel drug launch in the Beta lactam antibiotics will serve great opportunity for budding industries to reclaim new grounds to fortify their product portfolio. High segment will be the fastest growing market throughout the forecast period 2017-2025, due to the extensive growth in the Helicobacter pylori (clarithromycin-resistant), and Staphylococcus aureus, (methicillin-resistant, vancomycin-intermediate and resistant) infections and recent launch of novel drug formulation Pylera used to overcome clarithromycin resistance in peptic ulcer treatment; drugs such as linezolid, Daptomycin and Dalvabancin has effective mechanism of action in comparison to vancomycin in the antibiotic resistance treatment.
North America was observed as the largest market for multiple drug resistance bacterial infection treatment market in the base year 2021. According to Department of Health and Human Services of CDC report 2015 approximately 23,000 Americans die each year due to antimicrobial drug resistance; the growth is attributed mainly due to rising prevalence of multiple drug resistance cases, evolved health infrastructure and affordable reimbursement scenario. According to the European Centre for Disease Prevention and Control approximately 25,000 deaths were associated with multidrug resistant bacterial infection; the growth is chiefly attributed due to high public awareness regarding multiple drug resistance leading to early diagnosis and treatment, and supportive regulatory approval for launch of new antibiotics for the treatment of multiple drug resistance. Asia Pacific will be the fastest growing regional segment throughout the forecast period 2022-2030, the growth is attributed by factors like rising prevalence of geriatric population suffering with multiple drug resistance bacterial infection and increasing disposable income in these regions. Factors such as developing health infrastructure, increasing awareness regarding the judicious use of prescribed antibiotics especially in the remote areas are going to fuel the rapid growth of multiple drug resistance bacterial infection treatment market in Latin America and Middle East and Africa region in the near future.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Multiple Drug Resistance Bacterial Infection Treatment market are as follows:- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Multiple Drug Resistance Bacterial Infection Treatment market and their expected impact during the forecast period.
Market Segmentation
Vector
- Critical
- Acinetobacter baumanni (Carbapenem-Resistant)
- Pseudomonas aeruginosa (Carbapenem-Resistant)
- Enterobacteriaceae (Carbapenem-Resistant)
- Medium
- Enterococcus faecium (Vancomycin-Resistant)
- Helicobacter pylori (Clarithromycin-Resistant)
- Staphylococcus aureus (Methicillin-Resistant, Vancomycin Intermediate And Resistant)
- Neisseria gonorrhea (Cephalosporin-Resistant, Fluoroquinolone-Resistant)
- High
- Streptococcus pneumonia (Penicillin-Non-Susceptible)
- Haemophilus influenza (Ampicillin-Resistant)
- Shigella spp. (Fluoroquinolone-Resistant)
- Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
Drug Class
- Cephalosporin
- Cefixime (3rd Generation)
- Ceftriaxone (3rd Generation)
- Ceftobiprole (5th Generation)
- Beta Lactam
- Doripenem
- Imipenem
- Meropenem
- Ceftazidime
- Beta Lactamase Inhibitors
- Sulbactam
- Tazobactum
- Avibactum
- Clavam
- Oxazolidinone
- Linezolid
- Cyclic Lipopeptide
- Daptomycin
- Glycolipopeptides
- Dalbavancin
- Vancomycin
- Others
- Polymixins
- Tetracycline and Derivatives
- Penicillins
- Macrolides
- Macrolide-Lincosamide-Streptogramin
- Rifamycins
- Fluoroquinolones
- Nitroimidazole
- Bismuth Subcitrate Potassium
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Multiple Drug Resistance Bacterial Infection Treatment market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Multiple Drug Resistance Bacterial Infection Treatment market?
- Which is the largest regional market for Multiple Drug Resistance Bacterial Infection Treatment market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Multiple Drug Resistance Bacterial Infection Treatment market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Multiple Drug Resistance Bacterial Infection Treatment market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface
2. Executive Summary
3. Multiple Drug Resistance Bacterial Infection Treatment Market: Business Outlook & Market Dynamics
4. Multiple Drug Resistance Bacterial Infection Treatment Market: By Vector, 2020-2030, USD (Million)
5. Multiple Drug Resistance Bacterial Infection Treatment Market: By Drug Class, 2020-2030, USD (Million)
6. North America Multiple Drug Resistance Bacterial Infection Treatment Market, 2020-2030, USD (Million)
7. UK and European Union Multiple Drug Resistance Bacterial Infection Treatment Market, 2020-2030, USD (Million)
8. Asia Pacific Multiple Drug Resistance Bacterial Infection Treatment Market, 2020-2030, USD (Million)
9. Latin America Multiple Drug Resistance Bacterial Infection Treatment Market, 2020-2030, USD (Million)
10. Middle East and Africa Multiple Drug Resistance Bacterial Infection Treatment Market, 2020-2030, USD (Million)
11. Company Profile
List of Figures
List of Tables
Companies Mentioned
- Abbott Laboratories Inc.
- Actelion Pharmaceuticals Ltd.
- Albany Molecular Research Inc.
- Allergan plc
- AstraZeneca
- Bayer AG
- Biocon
- Daiichi Sankyo Company
- GlaxoSmithKline plc
- Macrolide Pharmaceuticals Inc.
- Merck & Co Inc.
- Pfizer Inc.
- Sanofi
- Teva Pharmaceuticals Industries Ltd.
- Wockhardt
- Zavante Therapeutics Inc.
